mFOLFOX regimen

DRUG3 trials

Sponsors

Fudan University, Zhejiang Cancer Hospital, UNICANCER

Conditions

Biliary Tract Cancer (BTC)Colorectal CarcinomaHepatocellular Carcinoma Stage IIIaLiver Metastases

Early Phase 1

Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC

Zhejiang Cancer HospitalHepatocellular Carcinoma Stage IIIa

Start: 2021-07-01End: 2023-06-30Target: 60Updated: 2021-08-16

Phase 2

Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers

Not yet recruitingNCT07437287

UNICANCERBiliary Tract Cancer (BTC)

Start: 2026-07-01End: 2031-10-01Target: 160Updated: 2026-02-27

Phase 3

mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases

RecruitingNCT04781270

Fudan UniversityColorectal Carcinoma, Liver Metastases

Start: 2021-04-15End: 2026-03-30Target: 308Updated: 2021-09-27

Related Papers

mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS mutant unresectable colorectal liver-limited metastases: A study protocol of a multicenter randomized controlled phase 3 (BECOME2) trial.

Journal of Clinical Oncology2022-01-19